The Latest Cardiac and Vascular News
The AEGIS-II trial is evaluating the efficacy and safety of CSL112 (apolipoprotein A-I [human]) during the high-risk 90-day period following a heart attack KING OF PRUSSIA, Pa., Nov. 5, 2020 /PRNewswire/ — Global biotherapeutics leader CSL Behring today announced that the study design manuscript for its landmark AEGIS-II (ApoA-I Event reducinG in Ischemic Syndromes II) has been […]
– Fiscal fourth quarter revenues of $4.784 billion grew 4.4% on a reported and currency-neutral basis. – BD’s COVID-19 testing sales totaled more than $440 million in the fourth fiscal quarter. – Fiscal fourth quarter GAAP EPS were $0.36. Non-GAAP EPS were $2.79. FRANKLIN LAKES, N.J., Nov. 5, 2020 /PRNewswire/ — […]
BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying mechanisms of cardiomyopathies. The MyoSeeds Program was founded […]
NIJMEGEN, Netherlands, Nov. 4, 2020 /PRNewswire/ — Saillant Therapeutics, an innovative preclinical stage biotechnology company developing promising small molecule-based therapies, today announced that it has obtained Proof of Concept for its lead compound (ST02) indicated for the treatment of heart failure. The compound was tested in a well-established preclinical heart failure model in which […]
CARLSBAD, Calif. and BOSTON, Nov. 3, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its wholly owned subsidiary Akcea Therapeutics, Inc., today announced that Pfizer Inc. (NYSE: PFE) has initiated a Phase 2b study of vupanorsen (AKCEA-ANGPTL3-LRx) in statin-treated patients with elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs). The study, Targeting ANGPTL3 with an antisense oligonucleotide in adults with dyslipidemia (TRANSLATE-TIMI […]
NEW YORK & BRISBANE, Calif.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all outstanding shares of […]
– The EnSite™ X EP System is a new cardiac mapping system designed from electrophysiologist input to optimize cardiac ablation procedures – System offers electrophysiologists a new platform of options to provide consistent performance, regardless of the patient’s cardiac anatomy ABBOTT PARK, Ill., Nov. 2, 2020 — Abbott today announced it […]
TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) — InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the appointment of Andrea Tommasoli as senior vice president of global sales and […]
Company provides physicians with first portfolio comprised of drug-eluting stent and drug-coated balloon for the treatment of patients with peripheral artery disease MARLBOROUGH, Mass., Nov. 2, 2020 /PRNewswire/ — Boston Scientific (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon, developed for the treatment […]
Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarter Topline data from trial anticipated Q2 2021 WESTMINSTER, Colo., Nov. 02, 2020 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported financial results […]
